BRIEF—GW Pharma to present data on Epidiolex

Cannabis giant GW Pharmaceuticals and US subsidiary Greenwich Biosciences will present data from the Phase III trials of Epidiolex (cannabidiol oral solution) in rare neuropsychiatric disorders at the American Academy of Neurology annual meeting in California.

The firm says it will present long-term safety and efficacy data as well as health economic data on the cost burden of Lennox-Gastaut syndrome (LGS) and Dravet syndrome in the USA.

CEO Justin Gover said: “With regulatory applications for Epidiolex accepted for review in both the USA and Europe, and an expected US launch in the second half of this year, this is a very exciting time for our company and those awaiting this new potential treatment option.”